To the Editor.—
As a practicing general pediatrician in a community hospital, I have used aerosolized ribavirin frequently for the treatment of lower respiratory distress in infants infected with respiratory syncytial virus.1 I therefore wish to comment on the letter by Guglielmo et al.1During the last few months, several hospitals in our area, including my own, have faced the same dilemma as Guglielmo and colleagues. There seems to be increasing pressure from hospital personnel to delineate further the risk of ribavirin exposure in the workplace, especially to women in their childbearing years. I do not believe the concerns expressed are a result of newly reported cases of teratogenic effects in humans, as I am aware of no case reports of teratogenic, embryolethal, or mutagenic effects in any primate species.I must assume that the new concerns center around the reports of Harrison et al2 in the
Harkness MJ. The Exposure of Health Care Workers to Ribavirin Aerosol. JAMA. 1989;262(14):1947. doi:10.1001/jama.1989.03430140061010
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: